{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.44","value":"68.6"},{"groupId":"OG001","spread":"21.93","value":"68.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"266"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Global Health Status"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.37","value":"67.7"},{"groupId":"OG001","spread":"21.00","value":"67.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Global Health Status"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.44","value":"84.7"},{"groupId":"OG001","spread":"19.54","value":"84.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.02","value":"80.1"},{"groupId":"OG001","spread":"22.67","value":"81.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.72","value":"83.1"},{"groupId":"OG001","spread":"24.72","value":"82.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.75","value":"77.3"},{"groupId":"OG001","spread":"29.09","value":"76.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.04","value":"79.2"},{"groupId":"OG001","spread":"19.03","value":"79.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.79","value":"79.0"},{"groupId":"OG001","spread":"21.36","value":"79.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.06","value":"88.0"},{"groupId":"OG001","spread":"17.25","value":"87.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"266"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.45","value":"83.6"},{"groupId":"OG001","spread":"21.03","value":"82.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.77","value":"84.7"},{"groupId":"OG001","spread":"22.50","value":"83.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.77","value":"79.8"},{"groupId":"OG001","spread":"23.63","value":"81.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.43","value":"27.0"},{"groupId":"OG001","spread":"24.71","value":"26.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.06","value":"30.5"},{"groupId":"OG001","spread":"25.39","value":"31.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.91","value":"2.7"},{"groupId":"OG001","spread":"9.62","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.61","value":"3.2"},{"groupId":"OG001","spread":"11.61","value":"3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.06","value":"16.0"},{"groupId":"OG001","spread":"23.97","value":"17.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.40","value":"17.8"},{"groupId":"OG001","spread":"27.15","value":"20.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.79","value":"14.3"},{"groupId":"OG001","spread":"24.88","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.54","value":"15.7"},{"groupId":"OG001","spread":"25.01","value":"17.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.86","value":"26.1"},{"groupId":"OG001","spread":"27.50","value":"25.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Sleep"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.67","value":"25.0"},{"groupId":"OG001","spread":"27.75","value":"27.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Sleep"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.21","value":"10.2"},{"groupId":"OG001","spread":"20.45","value":"11.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.46","value":"12.5"},{"groupId":"OG001","spread":"22.60","value":"12.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.55","value":"9.2"},{"groupId":"OG001","spread":"20.86","value":"11.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.16","value":"11.4"},{"groupId":"OG001","spread":"24.96","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.98","value":"7.0"},{"groupId":"OG001","spread":"15.00","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.74","value":"12.7"},{"groupId":"OG001","spread":"21.86","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.34","value":"12.2"},{"groupId":"OG001","spread":"20.37","value":"12.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"266"},{"groupId":"OG001","value":"267"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Baseline, Financial Difficulties"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.70","value":"11.8"},{"groupId":"OG001","spread":"22.69","value":"12.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"End of Treatment, Financial Difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"275"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) version 3 is a 30-item scale composed of both multi-item scales and single-item measures. These include 5 functional scales (physical functioning, role, cognitive functioning, emotional functioning, and social functioning), 3 symptom scales (fatigue, pain, and nausea/vomiting), a global health status scale, and 6 single items (constipation, diarrhea, sleep, dyspnea, appetite, financial). All scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Therefore, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status/QoL represents a high QoL. A high score for a symptom scale/item represents a high level of symptomatology/problems. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with follicular lymphoma (FL) were randomized to receive tafasitamab 12 milligrams per kilogram (mg/kg) intravenously (IV), administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg once daily (QD), administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/meters squared (m\\^2) IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL: Placebo + Rituximab + Lenalidomide"},{"description":"Participants with marginal zone lymphoma (MZL) were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG002","title":"MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG003","title":"MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"MEAN","populationDescription":"FL Full Analysis Set. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"up to approximately 34 months","title":"FL Population: EORTC QLQ-C30 Scores at Baseline and End of Treatment","type":"SECONDARY","unitOfMeasure":"scores on a scale"}